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ABSTRACT To better understand the innate immune response to Vibrio cholerae in-
fection, we tracked gene expression in the duodenal mucosa of 11 Bangladeshi
adults with cholera, using biopsy specimens obtained immediately after rehydration
and 30 and 180 days later. We identiﬁed differentially expressed genes and per-
formed an analysis to predict differentially regulated pathways and upstream regula-
tors. During acute cholera, there was a broad increase in the expression of genes as-
sociated with innate immunity, including activation of the NF-B, mitogen-activated
protein kinase (MAPK), and Toll-like receptor (TLR)-mediated signaling pathways,
which, unexpectedly, persisted even 30 days after infection. Focusing on early differ-
ences in gene expression, we identiﬁed 37 genes that were differentially expressed
on days 2 and 30 across the 11 participants. These genes included the endosomal
Toll-like receptor gene TLR8, which was expressed in lamina propria cells. Underscor-
ing a potential role for endosomal TLR-mediated signaling in vivo, our pathway anal-
ysis found that interferon regulatory factor 7 and beta 1 and alpha 2 interferons
were among the top upstream regulators activated during cholera. Among the in-
nate immune effectors, we found that the gene for DUOX2, an NADPH oxidase in-
volved in the maintenance of intestinal homeostasis, was upregulated in intestinal
epithelial cells during cholera. Notably, the observed increases in DUOX2 and TLR8
expression were also modeled in vitro when Caco-2 or THP-1 cells, respectively, were
stimulated with live V. cholerae but not with heat-killed organisms or cholera toxin
alone. These previously unidentiﬁed features of the innate immune response to V.
cholerae extend our understanding of the mucosal immune signaling pathways and
effectors activated in vivo following cholera.
KEYWORDS Vibrio cholerae, immune mechanisms, mucosal immunity
Vibrio cholerae O1 causes an estimated 3 million cases of cholera and 100,000 deathsper year (1). Despite progress under the Millennium Development Goals in pro-
viding access to safe drinking water, the global burden of cholera has increased (1, 2).
While infection with V. cholerae leads to protection against reinfection for up to 10
years, current vaccines provide more limited protection, especially in children under 5
years of age (3–5). The mechanisms through which infection with V. cholerae generates
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an innate immune response and long-lasting adaptive immunity are not completely
understood.
Unlike invasive enteric pathogens, such as Salmonella enterica or Shigella, V. cholerae
is noninvasive and does not cause clinically apparent, overt inﬂammation. Instead, V.
cholerae colonizes the small intestine and causes secretory diarrhea, mediated by the
action of cholera toxin (CT) on intestinal epithelial cells (6). Still, cholera is associated
with microscopic inﬂammatory changes of the human small intestine, which include
the widening of intercellular spaces, apical junction abnormalities, vascular congestion,
and an inﬂux of neutrophils, mast cells, eosinophils, macrophages, and activated
dendritic cells (7–9). In addition, a number of mucosal innate effector molecules,
including bactericidal proteins, defensins, lactoferrin, myeloperoxidase, and BPIFB1
(LPLUNC1) are expressed in response to V. cholerae infection (10–12).
A previous study of human duodenal RNA expression in cholera, using a microarray-
based method, demonstrated that the majority of genes upregulated during acute
illness were involved in the innate immune response (10). A subsequent proteomic
analysis of the human duodenal mucosa response to cholera demonstrated the up-
regulation of key innate immune signaling pathways, including activation of the
nuclear factor kappa B (NF-B), the NLRP3 inﬂammasome, and mitogen-activated
protein kinase (MAPK) signaling pathways (13). In addition, a genomic analysis found an
association between genetic variants under selection pressure in the NF-B and in-
ﬂammasome signaling pathways and susceptibility to cholera (14). Some of these
ﬁndings can be modeled in vitro using cells stimulated by coculture with toxin-
producing V. cholerae, which results in inﬂammatory responses mediated by activation
of the NF-B, MAPK, NLRP3, and STAT3 signaling pathways (15–17). Taken together,
these studies demonstrate a role for proinﬂammatory signaling pathways in the innate
immune response to cholera. However, previous studies represent only a partial view
of the mechanisms of innate immune activation in response to cholera.
To better understand the human innate immune response to cholera, we performed
the ﬁrst transcriptome sequencing (RNA-seq)-based measure of the mucosal transcrip-
tome in patients recovering from acute cholera. RNA-seq provides a higher resolution
and a less biased measure of RNA expression than the previously used array-based
method. In addition, unlike previous studies, we evaluated the transcriptional response
at an additional late time point, comparing the transcriptional response in duodenal
tissue during acute cholera with that at subsequent time points, at both 30 and 180
days after infection. Our results conﬁrmed that there is an increase in expression of
central innate immune signaling pathways and effectors in acute cholera. Novel
ﬁndings included the identiﬁcation of several previously unknown features of the
innate immune response to cholera, including the persistence of innate immune
activation at 30 days following cholera. As such, this study extends our understanding
of the human immune response to this globally important pathogen.
RESULTS
Patient and specimen characteristics. We obtained paired duodenal biopsy spec-
imens from 11 participants during acute cholera (day 2) and subsequently at day 30. We
obtained an additional biopsy specimen at day 180 for six of the participants. The
characteristics of the participants are listed in Table 1. Ten of the 11 participants were
male, and the median age was 30 years. All the participants presented to the Interna-
tional Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B), Hospital in Dhaka,
Bangladesh, within 24 h of developing watery diarrhea and had severe dehydration
upon presentation; on admission, cultures of stool specimens from all patients were
positive for V. cholerae O1 of the serotype shown in Table 1. As we have previously
observed, most participants demonstrated a signiﬁcant increase in the vibriocidal
antibody titer, though one individual did not develop an antibody response (18). Biopsy
specimens had a mean weight of 94 mg (range, 44 to 190 mg). RNA integrity numbers
(RIN) ranged from 5.8 to 8.8 (median 7.35). The sequencing depth ranged from 4.0
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million reads to 108.6 million reads per sample (median, 31.3 million reads per sample)
(see Table S1 in the supplemental material).
Transcriptomic proﬁling reveals upregulation of genes encoding innate im-
mune effectors and signaling molecules. There were 25,269 transcripts detected in
the duodenal mucosa in the cholera patients. A paired analysis comparing acute-phase
samples (day 2) and convalescent-phase samples (day 30) revealed heterogeneity in the
gene expression proﬁles between participants. Hierarchical clustering analysis identi-
ﬁed at least two distinct clusters of participants on the basis of their differential gene
expression patterns (Fig. 1). Despite this variation among individual participants, there
were still 37 differentially expressed genes for which the difference in expression
reached statistical signiﬁcance across the cohort after correction for multiple compar-
isons.
These differentially expressed genes included 17 whose expression increased and 20
whose expression decreased during acute cholera (Table 2). Of the 17 genes with
increased expression during cholera, 13 are known to be involved in the innate immune
response on the basis of the Gene Ontology database. These genes encode signaling
molecules involved in lymphocyte and neutrophil recruitment and activation (CXCL5
and CXCL9). Other differentially expressed genes encode the innate effector molecules
transcobalamin 1 (TCN1), complement factor B (CFB), lipocalin 2 (LCN2), and dual
oxidase 2 (DUOX2). Other genes with increased expression in acute cholera are involved
in the sensing of microbes and danger signals that lead to the activation of innate
signaling pathways. These included the gene encoding Toll-like receptor 8 (TLR8), an
endosomal Toll-like receptor (TLR) involved in sensing nucleic acids, and the gene
encoding guanylate binding protein 5 (GBP5), a regulator of the NLRP3 inﬂammasome.
Genes whose expression was decreased during acute cholera were diverse and in-
cluded those involved in retinol biosynthesis (LRAT), gluconeogenesis (PCK1), cell
proliferation and growth (TM4SF4), peptide digestion (ANPEP), and ketogenesis
(HMGCS2); a gene encoding an IgG Fc-binding protein that is abundant in mucus and
structurally related to mucin proteins (FCGBP); and genes involved in lipid metabolism
(APOC3, APOA4). The differential regulation of a subset of these genes was conﬁrmed
using quantitative reverse transcription-PCR (Table S2).
Among the six participants from whom an additional biopsy specimen was obtained
at day 180, we found that the number of genes with signiﬁcantly different levels of
expression between day 2 and day 180 (5,431 genes; n  6) was much larger than the
number that was apparent in the comparison of the day 2 and day 30 time points (37
genes, n  11). This was not explained simply by the subset of participants for whom
data were available at day 180, because data from the six participants evaluated in the
day 180 subset revealed only one gene for which the difference in expression reached
statistical signiﬁcance in the day 2 and day 30 comparison (CFB; P  0.00005). Instead,
the larger number of genes for which the difference in expression reached statistical
TABLE 1 Patient characteristics
Patient no. Age (yr) Sex Blood group
V. cholerae O1
serotype
Vibriocidal
antibody titer on:
Day 2 Day 7
1a 36 Male B Ogawa 5 5
2a 23 Male O Ogawa 160 320
3a 30 Male O Inaba 10 40
4a 31 Male B Ogawa 160 1,280
5 36 Male A Ogawa 10 640
6a 28 Male A Ogawa 5 320
7 38 Male O Ogawa 20 640
8a 27 Male A Ogawa 40 1,280
9 36 Male B Inaba 5 2,560
10 28 Male O Ogawa 40 320
11 24 Female O Ogawa 20 640
aParticipants included in the day 2, 30, and 180 comparisons.
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FIG 1 Heatmap representation of 103 genes in the duodenal mucosa of each of the study participants
differentially expressed when comparing the acute stage (day 2) to the convalescent stage (day 30) of
cholera. The genes are clustered on the basis of the similarity of the gene expression levels. The genes
included in this ﬁgure were differentially expressed (P 0.05, FDR 0.05) in at least 3 study participants.
A multiscale bootstrap resampling analysis was used for assessing hierarchical clustering, which revealed
that patients 1, 3, 5, and 7 formed a cluster which was statistically signiﬁcant (P  0.048). The numbers
at the bottom refer to the individual study participants.
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signiﬁcance was due to a robust difference in mucosal gene expression among a larger
number of transcripts when expression during acute cholera (day 2) was compared
with that at day 180. The majority of these differentially regulated genes (3,369 of
5,431, or 62%) demonstrated increased expression on day 2 relative to that on day
180 (Fig. 2).
To explore this time course further, we considered the top 100 genes most differ-
entially expressed between acute cholera and day 180 on the basis of statistical
signiﬁcance. Clustering analysis on the basis of their expression at the three time points
revealed at least four distinct patterns for the time course of gene expression (Fig. 3).
The majority of the genes (clusters A, B, and C) demonstrated their highest levels of
expression at day 2 and their lowest levels of expression at day 180. These three clusters
could be distinguished by their level of expression at day 30. The levels of expression
of some genes remained increased in at day 30 (cluster A, persistently increased), other
genes had intermediate levels of expression at day 30 (cluster B), and the expression of
some genes returned quickly to lower levels (cluster C, transiently increased). A smaller
set of genes (cluster D) demonstrated their peak level of increased expression at day 30.
Overall, these ﬁndings reveal persistent gene expression changes up to 30 days after
infection with V. cholerae, a novel ﬁnding not previously described in cholera.
TABLE 2 Genes differentially expressed between days 2 and 30 following cholera
Change in gene expression and gene Gene product
Log2 fold change
in expression P valuea
Increased expression on day 2
XIST Long noncoding RNA 7.35 0.0001
CXCL9 CXC chemokine 3 (lymphocyte chemoattractant) 1.96 0.00005
FCGR3A Receptor for Fc portion of IgG expressed on NK cells 1.95 0.00005
SERPINA3 Member of the serine protease inhibitor class 1.94 0.00005
CXCL5 CXC chemokine 5 (neutrophil activation and recruitment) 1.94 0.00005
LCN2 Lipocalin 2 (iron trafﬁcking protein) 1.8 0.00005
CFB Complement factor B 1.78 0.00005
DUOX2 Dual oxidase 2 1.57 0.00005
REG1A Regenerating islet-derived protein 1A 1.38 0.00005
TCN1 Transcobalamin I (vitamin B–12 binding protein) 1.32 0.0001
TLR8 Toll-like receptor 8 1.22 0.00005
ITM2C Integral membrane protein 2C 1.13 0.00005
BCMO1 Beta-carotene oxygenase 1 1.04 0.00015
SLC7A11 Solute carrier family 7 member 11 0.985 0.00015
GBP5 Guanylate binding protein 5 0.934 0.00015
CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5 0.915 0.0001
SPINK1 Serine peptidase inhibitor, Kazal type 1 0.901 0.00005
Decreased expression on day 2
APOC3 Apolipoprotein C3 2.99 0.00005
RNU12 Long noncoding RNA 2.34 0.00005
FCGBP Fc fragment of IgG binding protein 2.19 0.00015
TM4SF4 Intestine and liver tetraspan membrane protein 1.7 0.00005
HBB Beta hemoglobin 1.61 0.00005
CFL1 Colﬁlin-1 protein 1.58 0.00005
HMGCS2 3-Hydroxy-3-methylglutaryl coenzyme A synthase 2 1.55 0.00005
ANPEP Alanyl aminopeptidase 1.46 0.00005
UBC Ubiquitin C 1.29 0.00005
APOA4 Apolipoprotein A4 1.18 0.00005
HIST1H4C Histone cluster 1, H4c 1.15 0.0001
PCK1 Phosphoenolpyruvate carboxykinase 1 1.13 0.00005
UGT2B7 UDP-glucuronosyltransferase 2B9 1.12 0.00005
LRAT Lecithin retinol acyltransferase 1.09 0.00005
CYP2C18 Cytochrome P450, family 2, subfamily C, polypeptide 18 1.08 0.00005
EEF1G Eukaryotic translation elongation factor 1 gamma 1.07 0.00005
CTSE Cathepsin E 0.98 0.00005
ADH4 Alcohol dehydrogenase 4 0.95 0.0001
CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 0.91 0.0001
GSTA1 Glutathione S-transferase alpha 1 0.87 0.00005
aP values adjusted for multiple comparisons with a false discovery rate of 0.05.
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As expected, the set of genes that had transiently increased expression (cluster C)
overlapped the set of genes that were differentially expressed between days 2 and 30
in the data from the full cohort. Of the 17 genes whose expression was signiﬁcantly
increased when the expression for specimens collected on days 2 and 30 was com-
pared, 11 were in cluster C. Other genes in this category whose expression was
transiently increased included those for caspase-1 (CASP1), caspase-5 (CASP5; a regu-
lator of the NLRP3 inﬂammasome), and hexokinase 2 (HK2; a cytoplasmic sensor of
peptidoglycan and a regulator of the NLRP3 inﬂammasome).
Use of the InnateDB database to evaluate the ontogeny of genes differentially
regulated between acute cholera and day 180 revealed that 286 of the genes upregu-
lated during the acute phase of cholera were involved in the innate immune response,
149 genes were involved in apoptosis, 62 genes were involved in the cellular response
to DNA damage stimulus, 41 genes were involved in Toll-like receptor signaling, and 18
genes were involved in NF-B signaling. Furthermore, there was a broad upregulation
of TLRs, including TLRs 1 to 8 and 10. Of the genes found to be downregulated when
expression on day 2 was compared to that on day 180, 198 genes were involved in
metabolic processes, 180 genes were involved in the innate immune response, and 89
genes were involved in the apoptotic process (Table S3) (19).
Innate immune pathways and central innate immune signaling molecules
activated by V. cholerae. We used Ingenuity Pathway Analysis (IPA) to identify
biological pathways enriched by V. cholerae infection and predict the upstream tran-
scriptional regulators activated in the duodenal mucosa in response to cholera (Fig. 4A
and B). Using this approach, central innate immune pathways identiﬁed to be activated
during the acute phase of cholera included the NF-B signaling, MAPK signaling, TREM1
signaling, and stress-activated protein kinase (SAPK)/Jun N-terminal protein kinase
(JNK) signaling pathways. Toll-like receptor signaling was also enriched, as our data
demonstrated an upregulation of multiple Toll-like receptors, including cell surface
TLRs 1, 2, 4, 5, and 6, as well as the endosomal TLRs, including TLR3, TLR7, and TLR8.
In addition, there was increased expression of TLR10 during the acute phase of cholera.
Our analysis also revealed an enrichment of expression of genes involved in the
production of nitric oxide and reactive oxygen species.
We also used IPA to predict which cytokines and transcription factors may be
activated during cholera (Table 3). The top upstream cytokines predicted to be acti-
FIG 2 Volcano plot of RNA-seq data demonstrating differentially expressed genes in acute-phase (day 2 [d2]) versus convalescent-phase (day 30 [d30]) samples
(A), acute-phase (day 2) versus day 180 (d180) samples (B), and day 30 versus day 180 samples (C). The y axis values show the negative logarithm base 10 of
the P value. The x axis is shown as the log2 difference in estimated relative expression values. The red dots represent reads with a statistically signiﬁcant
difference in expression, deﬁned as a P value of 0.05 and an FDR of 0.05.
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FIG 3 Heatmap representing the gene expression values (FPKM) of the top differentially expressed genes
across the 3 time points: days 2, 30, and 180. The genes in cluster A demonstrated persistently increased
expression at day 30. The genes in cluster B demonstrated increased expression at day 2 and interme-
diate levels of expression at day 30. The genes in cluster C demonstrated a transient increase in
expression at day 2 and lower levels of expression at days 30 and 180. The genes in cluster D had
increased expression at day 30 compared to that at day 2 and day 180.
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vated during cholera were gamma interferon, alpha 2 interferon, beta 1 interferon,
interleukin-1 (IL-1), IL-6, oncostatin-M (OSM), colony-stimulating factor 2 (CSF2),
IL-21, and IL-23. The top upstream transcriptional regulators predicted to be activated
during acute cholera were interferon regulatory factor 7 (IRF7) and STAT1.
Immunostaining for DUOX2 and TLR8 demonstrates expression in the duode-
nal mucosa. One of the genes with the most robustly increased expression during
acute cholera, DUOX2, encodes an oxidase that produces bactericidal reactive oxygen
species and is an effector of the inﬂammasome-mediated antibacterial response (20).
FIG 4 Canonical pathways predicted by IPA to be activated or inhibited in the duodenal mucosa of patients with cholera, comparing the results for expression
on days 2 and 30 (A) or days 2 and 180 (B). Pathways predicted to be activated are in orange, and the blue bars correspond to pathways predicted to be
inhibited (based on the Z-scores determined by IPA). The red line denotes the threshold of statistical signiﬁcance [P  0.05 or log(P value)  1.3]. PI3K,
phosphatidylinositol 3-kinase; NFAT, nuclear factor of activated T cells; EIF2, eukaryotic initiation factor 2; LXR, liver X receptor; RXR, retinoid X receptor; PPAR,
peroxisome proliferator-activated receptor; HGF, hepatocyte growth factor; ILK, integrin-linked kinase.
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We examined the expression of DUOX2 in the human duodenal mucosa in acute- and
convalescent-phase cholera using immunohistochemistry (IHC). The robust expression
of DUOX2 was seen in the epithelial cells of the duodenal surface during the acute
phase of cholera. Sections obtained at the acute and convalescent (day 30) phases
clearly differed in their immunostaining for DUOX2 (Fig. 5). Quantiﬁcation of the
expression of DUOX2 in the duodenal tissue sections showed a statistically signiﬁcant
increase in expression (n  3 subjects at each time point, with three sections per
subject per time point; mean, 8,152 cells/mm2 in day 2 specimens versus 4,237
cells/mm2 in day 30 specimens; P  0.0310).
TLR8 expression was also increased during acute cholera. However, the role of TLR8
in cholera pathogenesis is unknown, and we sought to further deﬁne its expression in
the duodenal mucosa of cholera patients. TLR8 is expressed in intracellular vesicular
membranes of monocytes, macrophages, and myeloid dendritic cells (21). Using IHC,
we examined the expression of TLR8 in acute-phase (day 2) duodenal tissue sections
and compared this to that in convalescent-phase (day 30) specimens. TLR8 expression
was predominantly seen in the lamina propria of the duodenal mucosa during the
acute phase of cholera and not in epithelial cells (Fig. 6). There was a trend toward
increased expression of TLR8 in the acute-phase specimens (P  0.07; mean, 2,685
cells/mm2 in day 2 specimens versus 1,513 cells/mm2 in day 30 specimens).
In vitro models also demonstrate increased expression of DUOX2 and TLR8 in
response to stimulation with live V. cholerae O1. Using polarized Caco-2 epithelial
cells, the expression of DUOX2 was increased following stimulation with live, toxin-
producing V. cholerae O1 relative to that following stimulation with heat-inactivated V.
cholerae O1, CT, or medium alone (Fig. 7A). Using phorbol myristate acetate (PMA)-
stimulated THP-1, macrophage-like cells, we similarly found that TLR8 gene expression
was increased in cells stimulated with live, toxin-producing V. cholerae O1 compared
with cells stimulated with heat-inactivated V. cholerae O1, CT, or medium alone
(Fig. 7B).
DISCUSSION
We conducted the ﬁrst analysis of the human mucosal transcriptional response to V.
cholerae infection using RNA-seq. Our results demonstrate the increased expression of
genes involved in central pathways of the innate immune response during acute
cholera. While prior work has shown a prominent role of the innate immune response
during acute infection with V. cholerae, the present study provides a broader look into
the human mucosal transcriptome and reveals novel components of innate immune
signaling pathways during the acute phase of cholera (10, 13, 14). Important ﬁndings
of this study include a persistence of gene expression 30 days after initial infection with
V. cholerae, activation of components of the innate immune response not previously
TABLE 3 Top upstream regulators predicted by IPA to be activated during choleraa
Upstream regulator Type
Days 2 to 30 Days 2 to 180
Z-score P value Z-score P value
Oncostatin-M (OSM) Cytokine 3.299 1.61E11 3.657 1.10E09
IRF7 Transcription regulator 3.236 9.77E05 2.795 1.88E03
IL-1 Cytokine 3.217 4.61E16 3.961 2.00E09
Gamma interferon Cytokine 3.087 2.94E24 2.936 4.44E13
IL-6 Cytokine 2.955 3.92E16 NS NS
STAT1 Transcription regulator 2.945 9.32E14 NS NS
Beta 1 interferon Cytokine 2.786 6.51E07 NS NS
CSF2 Cytokine 2.602 1.22E10 3.656 7.54E13
Tumor necrosis factor Cytokine 2.599 7.34E16 NS NS
Alpha 2 interferon Cytokine 2.570 2.18E05 NS NS
REL Transcription regulator NS NS 2.739 1.77E02
IL-21 Cytokine NS NS 2.733 7.64E03
IL-23 Cytokine NS NS 2.611 1.91E02
aDefault IPA settings were used to generate the list, which was then restricted to include cytokines and
transcriptional regulators only. NS, nonsigniﬁcant.
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FIG 5 Immunohistochemistry demonstrating the expression of DUOX2 during acute cholera in parafﬁn-preserved duodenal tissue biopsy
specimens. DUOX2 expression localized to the epithelial surface (arrowheads), and expression of DUOX2 in the duodenal mucosa during the acute
phase of cholera (A to C) was observed to be increased compared to that during the convalescent phase (D to F) (n  3 subjects at each time
point with three sections per subject per time point; mean  8,152 cells/mm2 in day 2 specimens versus 4,237 cells/mm2 in day 30 specimens;
P  0.0310). The sections obtained during the acute and convalescent phases shown in the ﬁgure were obtained from the same individual. The
images were captured using a TissueFAXS slide scanner, which captures many microscopic ﬁelds of view (FOV) over large areas of each tissue
section with a high-resolution camera and then aligns each FOV to create a large single view (montage) of the entire tissue section. At high
magniﬁcations, the boundaries (lines) between adjacent ﬁelds of view might be visible due to slight misalignments during the slide scanning
process, and these amount to only a few micrometers of overlap of adjacent FOV.
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described in the human immune response to V. cholerae, and the fact that activation
of some of the genes may be dependent on live toxigenic V. cholerae rather than
heat-inactivated bacteria.
Unexpectedly, the activation of central inﬂammatory pathways persisted even at 30
days after infection. This suggests that despite the rapid resolution of symptoms in
cholera, infection leads to a prolonged disruption of intestinal homeostasis persisting
for over a month. As such, our study provides an unexpected demonstration of how a
single episode of noninvasive, secretory diarrhea may result in prolonged changes in
the mucosal immune system. Considering the epidemiologic association between
repeated episodes of secretory diarrhea and the development of chronic enteropathy
in childhood, our ﬁnding of persistent immune activation following cholera is partic-
ularly notable (22). While the consequence of persistent immune activation following
infection is unknown, the question of whether this state could be detrimental or
perhaps provide protection from reinfection or infection with other enteropathogens
warrants further investigation. More generally, our results build on previous studies to
shed light on the speciﬁc features of the innate immune response to cholera (13). These
features of the innate response include the array of pattern recognition receptors,
signaling pathways, and innate immune effectors which are expressed or activated in
response to infection. Thus, this study identiﬁes a broad range of innate immune
signaling pathways activated in the human intestinal mucosa during infection with V.
cholerae.
FIG 6 Immunohistochemistry demonstrating TLR8 expression during acute cholera in parafﬁn-preserved duodenal tissue biopsy speci-
mens. TLR8 expression is observed predominantly in the lamina propria of the duodenal mucosa during acute cholera (A, C, and D), with
a trend toward increased expression in the acute phase of cholera compared to that in the convalescent phase (B) (n  3 subjects at each
time point with three sections per subject per time point; mean, 2,685 cells/mm2 in day 2 specimens versus 1,513 cells/mm2 in day 30
specimens; P 0.071). Arrowheads, examples of strongly positively staining cells. The specimens in this ﬁgure include tissue sections from
multiple subjects, and given that there was not a robust expression of TLR8, multiple high-power ﬁelds of acute-phase specimens were
included to adequately demonstrate the TLR8 expression that we observed.
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Together, our ﬁndings and those of previous studies indicate that multiple
pathogen- and danger signal-sensing mechanisms are likely engaged when live V.
cholerae O1 interacts with the intestinal mucosa. Previous in vitro studies have dem-
onstrated that V. cholerae O1 activates multiple cell surface TLR/MyD88 signaling
pathways. These signaling events include V. cholerae O1 lipopolysaccharide (LPS),
which signals via TLR4, and cytolysin (HlyA), which signals via TLR2/TLR6 heterodimers
(13, 23, 24). Because V. cholerae possesses a sheathed ﬂagellum, it is less clear whether
TLR5-mediated signaling contributes to the response (25). In addition, it remains
unclear whether lipid A modiﬁcations that occur in vivo can impact TLR4 signaling (26).
However, on the basis of the increased expression of several cell surface TLRs, including
TLRs 2, 4, 5, and 6, during acute cholera and a sustained increase in NF-B pathway
FIG 7 (A) Intestinal epithelial cells (a polarized Caco-2 cell monolayer) stimulated with V. cholerae O1
exhibited increased expression of DUOX2 compared to that by cells in medium alone, cells stimulated
with heat-inactivated V. cholerae O1, and cells stimulated with cholera toxin alone (P  0.038, P  0.024,
and P  0.025, respectively). (B) THP-1 cells differentiated to macrophages were stimulated with V.
cholerae O1, heat-inactivated V. cholerae O1, and cholera toxin alone. Macrophages showed increased
expression of TLR8 following stimulation with live V. cholerae O1 compared to that following stimulation
with medium alone, heat-inactivated V. cholerae O1, and cholera toxin alone (P  0.026, P  0.004, and
P  0.032, respectively).
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activation following cholera, this study provides further evidence that multiple cell
surface TLR/MyD88-dependent signaling pathways may contribute to the sustained
activation of NF-B signaling (6, 25, 27).
Our present study also provides new in vivo evidence that endosomal TLRs may play
a role in the innate immune response to cholera. This study is the ﬁrst to demonstrate
the coordinated activation of a broad range of cell surface and endosomal TLRs in the
setting of V. cholerae infection. In particular, we found an increase in the expression of
genes for endosomal TLRs, including TLR3, TLR7, TLR10, and TLR8. In the setting of
cholera, the upregulation of the endosomal TLRs is a novel ﬁnding, and TLR8 exhibited
the greatest change in expression between the acute and convalescent phases of
cholera. This is notable, because unlike cell surface TLRs, endosomal TLR signaling
results in the downstream production of type I interferons through an IRF7-dependent
signaling pathway (21). Thus, our ﬁnding that IRF7 and beta 1 and alpha 2 interferons
were among the top predicted activated upstream regulators suggests the potential
relevance of this pathway in the immune response to V. cholerae infection.
The potential physiologic relevance of these ﬁndings is underscored by our obser-
vation that TLR8 expression is increased in differentiated THP-1 cells upon stimulation
with toxigenic V. cholerae O1. Interestingly, neither heat-inactivated V. cholerae O1 nor
CT alone resulted in a robust increase in the expression of TLR8. This suggests that the
induction of TLR8 expression may depend on bacterial viability. Interestingly, it has
recently been shown that bacterial RNA activates TLR8 and that both Escherichia coli
and the phagocytosis of Helicobacter pylori induce TLR8 activation in human cell culture
models of infection (28, 29). Thus, the differential expression of TLR8 in response to
stimulation with live V. cholerae O1 could reﬂect a requirement for sensing bacterial
RNA, which is rapidly lost in heat-killed bacteria (30). Considering these results together,
our ﬁndings suggest that increased TLR8 expression during acute cholera may provide
an important endosomal TLR signaling pathway that is speciﬁc to live bacteria and
relevant to the activation of the IRF7/type I interferon response that appears to be a
hub of the innate immune response in human cholera.
In addition to TLR-mediated pathogen sensing and activation of the NF-B and IRF7
transcription factors, our study suggests that the NLRP3 inﬂammasome is another
major hub of the innate immune response to cholera. Previously, we and others have
demonstrated that CT leads to activation of the NLRP3 inﬂammasome in LPS-primed
murine macrophages and that this activation is dependent on noncanonical activation
by caspase-11 (14, 31). In this study, we found that both the gene for caspase-5 (one
of two human orthologs of murine caspase-11) and GBP5 (a regulator of the NLRP3
inﬂammasome assembly that responds to soluble bacterial cell wall components [32])
were increased in expression during acute cholera. This ﬁnding is consistent with the
ﬁndings of previous studies by our group demonstrating that IL-1 production is
increased in lamina propria lymphocytes during acute cholera and with the ﬁndings of
the current IPA analysis that predicts that IL-1 is one of the top upstream regulators
activated during acute cholera.
In addition to these ﬁndings, we observed novel aspects of the effector arm of the
innate mucosal antibacterial response following cholera. In particular, the robust
activation of DUOX2 highlights a potential role of reactive oxygen species and oxidative
stress in the pathogenesis of cholera. While it has not previously been shown to play
a role during cholera speciﬁcally, DUOX2 impacts the maintenance of intestinal ho-
meostasis, and its aberrant expression has been linked to inﬂammatory bowel disease
(33). Germfree mice receiving a dysbiotic microbiota but not those receiving a healthy
microbiota exhibited increased expression of DUOX2, suggesting that it is an important
modulator of the host-microbiota interaction (34). Thus, the robust but transient
upregulation of DUOX2 following infection with V. cholerae, which we conﬁrmed both
in Caco-2 cells in vitro and in epithelial cells in immunohistochemical analysis, may
modulate the changes in the microbiome induced by cholera (35).
Some limitations of this study also merit consideration. Our study cohort included
only 11 participants and 6 subjects from whom a biopsy specimen was obtained at 180
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days after infection. These participants demonstrated heterogeneous gene expression
proﬁles. Nevertheless, we were still able to identify signiﬁcant changes in gene expres-
sion across the cohort, and our results were consistent with those of previous studies
of the immune response in the duodenal mucosa of patients infected with V. cholerae
O1 performed using other methods (10, 13). One limitation of this study is the lack of
uninfected, matched controls, as we were unable to obtain specimens from such
individuals. However, the longitudinal design of this study, with samples being ob-
tained 180 days after infection, serves as a control to assess the acute changes in
transcription due to V. cholerae infection. In addition, the in vitromodels serve to further
support key observations in these participants. Another limitation of our study is that
the participants received medical therapy, including antibiotics and ﬂuid resuscitation,
which may have confounded the changes in gene expression at the mucosal surface.
Additionally, the subjects in this study reside in a region where there is an elevated
incidence of enteric infections, including infections caused by pathogens other than V.
cholerae, and coinfection may serve as a potential confounder. However, cultures of
stool specimens were performed for each individual to evaluate them for other enteric
pathogens, and if such pathogens were identiﬁed, they were excluded from the study.
Finally, while samples were taken from the duodenum, colonization by V. cholerae also
occurs at more distal sites in the small intestine (36).
Despite these limitations, our investigation provides a novel vantage point from
which to evaluate the innate immune response to V. cholerae infection in its natural
human host. We found that cholera induces a robust inﬂammatory response in the
intestinal mucosa, with gene expression changes persisting for at least 30 days after
infection. Our results suggest potential novel mechanisms for the activation of several
central pathways of the mucosal innate immune response, notably, those involved in
pathogen sensing via both endosomal TLR signaling and regulation of the NLRP3
inﬂammasome. Further study is needed to determine which of these early responses to
V. cholerae O1 are critical for successful pathogen eradication in the short term as well
as the subsequent generation of long-term adaptive immunity that follows cholera.
MATERIALS AND METHODS
Participant enrollment and collection of duodenal biopsy specimens. Adults presenting to the
International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B), in Dhaka, Bangladesh, with
severe acute watery diarrhea due to V. cholerae O1 infection were recruited for this study. Those who
agreed to participate underwent a screening history and physical examination, including laboratory
testing. All adults with culture-conﬁrmed cholera due to V. cholerae O1 infection, no other underlying
conditions, and no evidence of coinfection with another enteric pathogen were eligible for the study. For
each individual, stool studies were done to assess the subject for infections with other enteropathogens,
and if any such enteropathogens were identiﬁed, the subject was excluded from the study. All
participants received antibiotics and intravenous ﬂuids as part of the standard of care for cholera. Once
the participants were fully rehydrated (within 24 h of presentation), we collected six duodenal pinch
biopsy specimens from the second part of the duodenum by esophagogastroduodenoscopy (EGD). We
then collected convalescent-phase biopsy specimens 30 and 180 days later from the same subjects.
Tissue was stored in RNAlater solution (Qiagen, Hilden, Germany) at 80°C, and one biopsy specimen
from each time point was preserved in parafﬁn. The ICDDR,B Ethical and Research Review Committees
and Massachusetts General Hospital’s Institutional Review Board approved the study.
Sample preparation, RNA sequencing, and differential expression analysis. We homogenized
the biopsy specimens in TRIzol reagent (Life Technologies, Carlsbad, CA, USA) and performed RNA
extractions according to the manufacturer’s recommendations (37). We removed rRNA with an Illumina
Ribo-Zero rRNA removal kit (Illumina, Inc. San Diego, CA, USA) and conﬁrmed the RNA quality using an
Agilent bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA). We constructed cDNA libraries using
a PrepX RNA-seq for Illumina Library kit. We sequenced these libraries as 100-bp single-end reads on an
Illumina HiSeq 2500 instrument.
Differential expression and pathway analysis. We aligned the sequencing reads to the sequence
of a human reference genome, UCSC Hg19, using the TopHat2 program, annotating exons and
calculating the values of the number of fragments per kilobase per million (FPKM). We analyzed
differential gene expression with the Cufﬂinks/Cuffdiff program, comparing the transcriptome during
acute cholera with that in samples collected on day 30 and day 180 (38, 39). We considered genes to be
differentially expressed when the log2 fold change met the threshold for signiﬁcance with a P value of
0.05 adjusted for a false discovery rate (FDR) of 0.05 and using the Benjamini-Hochberg correction
for multiple testing. We conﬁrmed the differential expression of selected genes using real-time quanti-
tative PCR with SYBR green. We used a hierarchical clustering analysis to identify distinct clusters of
subjects based on their gene expression proﬁles. We evaluated for pathway enrichment and the activity
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of upstream regulators using Qiagen Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, CA)
commercial software (40). For this analysis, we used gene expression data sets comparing day 2 versus
day 30 specimens and day 2 versus day 180 specimens as input for IPA with the log2 fold change and
adjusted P values (using FDR cutoffs of 0.05 and 0.01 for the respective analyses). We implemented the
IPA analysis using the software manufacturer’s default settings.
Immunostaining and image analysis. We performed immunohistochemistry (IHC) to screen for
DUOX2 and TLR8 expression using 5-m parafﬁn-preserved sections. A total of three tissue sections from
three different patients from both the day 2 and day 30 time points were included. Slides were
deparafﬁnized, blocked with dual endogenous enzyme block (DEEB) 5= (Dako Agilent, Santa Clara, CA,
USA), and then incubated with either polyclonal anti-DUOX2 antibody (Thermo Fisher, Rockford, IL, USA)
or polyclonal anti-TLR8 antibody (Pro-Sci, Poway, CA, USA) at a 1:250 dilution. The slides were incubated
with a secondary antibody, a horseradish peroxidase-conjugated anti-rabbit immunoglobulin polymer
with hematoxylin as a counterstain. We obtained high-resolution images using a TissueFAXS slide-
scanning platform, quantiﬁed the staining using HistoQuest software (TissueGnostics, Vienna, Austria),
and included a measure of nuclear staining to allow reliable cell counting. We quantiﬁed the mean
intensity of each marker and enumerated positively staining cells to calculate the number of target
protein-expressing cells per square millimeter for each section of tissue. We then determined the
signiﬁcance of the differences between acute-phase (day 2) and convalescent-phase (day 30) samples
using a paired t test.
The images were generated using a TissueFAXS slide scanner (TissueGnostics USA), which captures
microscopic ﬁelds of view (FOV) of the tissue section in the x-y plane using a Zeiss Axio Imager Z2
microscope with a motorized stage and high-resolution camera (Baumer HXG40c HX series CMOS 16-bit
color camera). These FOV are then stitched together to create a single large image (or montage) of the
entire tissue region for cell identiﬁcation and quantiﬁcation. The stitching process involves alignment of
a certain amount of overlap of each FOV image and must be carefully calibrated for a given microscope
objective and camera.
In vitro cell culture stimulation assays. We cultured human monocytic THP-1 cells in RPMI with
20% heat-inactivated fetal bovine serum (FBS) and 1% Gibco antibiotic-antimycotic mixture (10,000
units/ml of penicillin, 10,000 g/ml of streptomycin, 25 g/ml of amphotericin B) at 37°C in 5% CO2. We
then seeded 24-well culture plates with 5  105 cells/ml, added phorbol myristate acetate (PMA) at a
concentration of 10 ng/ml, and incubated the plates for 48 h to allow the cells to differentiate into
human macrophage-like cells. We also cultured human intestinal epithelial Caco-2 cells in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) with FBS and the antibiotic-antimycotic mixture described above. We
seeded the Caco-2 cells at 1  106 cells/ml and incubated them at 37°C in 5% CO2 for 15 days to allow
the formation of a polarized epithelial cell monolayer. To stimulate the cells, we grew live V. cholerae O1
bacteria (reference strain N16961) under ToxR-inducing conditions as described previously (41). The
bacterial cultures were then centrifuged and suspended in medium. We stimulated the THP-1 or Caco-2
cells with 100 l of live V. cholerae O1, 100 l of heat-inactivated V. cholerae O1 (1.5  108 CFU/ml), or
puriﬁed CT (List Biological Laboratories, Campbell, CA, USA) at a concentration of 1 g/ml for 1 h. We
added kanamycin at 50 g/ml to each well and incubated the cells for an additional 24 h. We then
removed the supernatant, extracted the RNA, and prepared the cDNA library as described above.
Oligonucleotide primers speciﬁc for TLR8 and DUOX2 were constructed (see Table S4 in the supplemental
material), and quantitative PCR was carried out using SYBR green and -actin as a reference gene. We
assessed the statistical signiﬁcance of the gene expression changes using a paired t test.
Data availability. The complete database, including the fastq ﬁles, from this study has been
uploaded for public use and is available at the NIH BioProject page at http://www.ncbi.nlm.nih.gov/
bioproject/415406 (BioProject accession number PRJNA415406).
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